{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:11:59Z","timestamp":1790061119954,"version":"4.0.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP 21K16022"],"award-info":[{"award-number":["JP 21K16022"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-03002-0","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T15:01:36Z","timestamp":1716044496000},"page":"907-917","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Statins use and recurrent venous thromboembolism in the direct oral anticoagulant era: insight from the COMMAND VTE Registry-2"],"prefix":"10.1007","volume":"57","author":[{"given":"Hiroshi","family":"Mabuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2583-1321","authenticated-orcid":false,"given":"Yugo","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuki","family":"Chatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriaki","family":"Inoko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Takase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Oi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Takada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Otsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Ogihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Usami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyonori","family":"Togi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimichi","family":"Koitabashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Hiramori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Doi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Tsuyuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Takabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisato","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Sueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Shioyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Dohke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihisa","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,18]]},"reference":[{"issue":"1","key":"3002_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.advms.2022.10.002","volume":"68","author":"M Oleksiuk-B\u00f3jko","year":"2023","unstructured":"Oleksiuk-B\u00f3jko M, Lisowska A (2023) Venous thromboembolism: why is it still a significant health problem? Adv Med Sci 68(1):10\u201320. https:\/\/doi.org\/10.1016\/j.advms.2022.10.002","journal-title":"Adv Med Sci"},{"issue":"6","key":"3002_CR2","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ et al (2021) Antithrombotic therapy for VTE Disease: second update of the CHEST Guideline and Expert Panel Report. Chest 160(6):e545\u2013e608. https:\/\/doi.org\/10.1016\/j.chest.2021.07.055","journal-title":"Chest"},{"key":"3002_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/circresaha.116.308537","volume":"120","author":"A Oesterle","year":"2017","unstructured":"Oesterle A, Laufs U, Liao JK (2017) Pleiotropic effects of statins on the Cardiovascular System. Circ Res 120:229\u2013243. https:\/\/doi.org\/10.1161\/circresaha.116.308537","journal-title":"Circ Res"},{"key":"3002_CR4","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1160\/th04-02-0064","volume":"91","author":"A Undas","year":"2004","unstructured":"Undas A, Celi\u0144ska-L\u00f6wenhoff M, Kaczor M, Musial J (2004) New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost 91:1065\u20131077. https:\/\/doi.org\/10.1160\/th04-02-0064","journal-title":"Thromb Haemost"},{"key":"3002_CR5","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.0000151647.14923.ec","author":"A Undas","year":"2005","unstructured":"Undas A, Brummel-Ziedins KE, Mann KG (2005) Statins and blood coagulation. Arterioscler Thromb Vasc Biol. https:\/\/doi.org\/10.1161\/01.atv.0000151647.14923.ec. 25:287\u2009\u2013\u200994","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3002_CR6","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1093\/eurheartj\/ehy014","volume":"39","author":"JS Biedermann","year":"2018","unstructured":"Biedermann JS, Kruip M, van der Meer FJ, Rosendaal FR, Leebeek FWG, Cannegieter SC et al (2018) Rosuvastatin use improves measures of coagulation in patients with venous thrombosis. Eur Heart J 39:1740\u20131747. https:\/\/doi.org\/10.1093\/eurheartj\/ehy014","journal-title":"Eur Heart J"},{"key":"3002_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1161\/circulationaha.112.145334","volume":"127","author":"F Violi","year":"2013","unstructured":"Violi F, Calvieri C, Ferro D, Pignatelli P (2013) Statins as antithrombotic drugs. Circulation 127:251\u2013257. https:\/\/doi.org\/10.1161\/circulationaha.112.145334","journal-title":"Circulation"},{"key":"3002_CR8","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1056\/nejmoa0900241","volume":"360","author":"RJ Glynn","year":"2009","unstructured":"Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr., Kastelein JJ et al (2009) A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360:1851\u20131861. https:\/\/doi.org\/10.1056\/nejmoa0900241","journal-title":"N Engl J Med"},{"key":"3002_CR9","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/s2352-3026(16)30184-3","volume":"4","author":"SK Kunutsor","year":"2017","unstructured":"Kunutsor SK, Seidu S, Khunti K (2017) Statins and primary prevention of venous thromboembolism a systematic review and meta-analysis. Lancet Haematol 4:e83\u2013e93. https:\/\/doi.org\/10.1016\/s2352-3026(16)30184-3","journal-title":"Lancet Haematol"},{"key":"3002_CR10","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1093\/eurheartj\/eht046","volume":"34","author":"S Biere-Rafi","year":"2013","unstructured":"Biere-Rafi S, Hutten BA, Squizzato A, Ageno W, Souverein PC, de Boer A et al (2013) Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J 34:1800\u20131806. https:\/\/doi.org\/10.1093\/eurheartj\/eht046","journal-title":"Eur Heart J"},{"key":"3002_CR11","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1160\/th15-10-0775","volume":"115","author":"V Tagalakis","year":"2016","unstructured":"Tagalakis V, Eberg M, Kahn S, Azoulay L (2016) Use of statins and reduced risk of recurrence of VTE in an older population. A population-based cohort study. Thromb Haemost 115:1220\u20131228. https:\/\/doi.org\/10.1160\/th15-10-0775","journal-title":"Thromb Haemost"},{"key":"3002_CR12","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.amjcard.2019.10.011","volume":"125","author":"Y Yoshikawa","year":"2020","unstructured":"Yoshikawa Y, Yamashita Y, Morimoto T, Mabuchi H, Amano H, Takase T et al (2020) Effect of statins on recurrent venous thromboembolism (from the COMMAND VTE Registry). Am J Cardiol 125:189\u2013197. https:\/\/doi.org\/10.1016\/j.amjcard.2019.10.011","journal-title":"Am J Cardiol"},{"key":"3002_CR13","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.thromres.2012.08.296","volume":"130","author":"A Delluc","year":"2012","unstructured":"Delluc A, Tromeur C, Le Moigne E, Nowak E, Mottier D, Le Gal G et al (2012) Lipid lowering drugs and the risk of recurrent venous thromboembolism. Thromb Res 130:859\u2013863. https:\/\/doi.org\/10.1016\/j.thromres.2012.08.296","journal-title":"Thromb Res"},{"key":"3002_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/rth2.12003","volume":"1","author":"SK Br\u00e6kkan","year":"2017","unstructured":"Br\u00e6kkan SK, Caram-Deelder C, Siegerink B, van Hylckama Vlieg A, le Cessie S, Rosendaal FR et al (2017) Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study. Res Pract Thromb Haemost 1:112\u2013119. https:\/\/doi.org\/10.1002\/rth2.12003","journal-title":"Res Pract Thromb Haemost"},{"key":"3002_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejim.2023.08.007","volume":"118","author":"K Kaneda","year":"2023","unstructured":"Kaneda K, Yamashita Y, Morimoto T, Chatani R, Nishimoto Y, Ikeda N et al (2023) Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants. Eur J Intern Med 118:59\u201372. https:\/\/doi.org\/10.1016\/j.ejim.2023.08.007","journal-title":"Eur J Intern Med"},{"key":"3002_CR16","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/nejmoa1306638","volume":"369","author":"HR B\u00fcller","year":"2013","unstructured":"B\u00fcller HR, D\u00e9cousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH et al (2013) Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 369:1406\u20131415. https:\/\/doi.org\/10.1056\/nejmoa1306638","journal-title":"N Engl J Med"},{"key":"3002_CR17","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3:692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"key":"3002_CR18","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1253\/circj.cj-17-1128","volume":"82","author":"Y Yamashita","year":"2018","unstructured":"Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K et al (2018) Anticoagulation therapy for venous thromboembolism in the Real World\u3000- from the COMMAND VTE Registry. Circ J: Official J Japanese Circulation Soc 82:1262\u20131270. https:\/\/doi.org\/10.1253\/circj.cj-17-1128","journal-title":"Circ J: Official J Japanese Circulation Soc"},{"key":"3002_CR19","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP et al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 41:543\u2013603. https:\/\/doi.org\/10.1093\/eurheartj\/ehz405","journal-title":"Eur Heart J"},{"key":"3002_CR20","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Kreuziger LB, Bounameaux H, Doerschug K, Geersing GJ et al (2021) Antithrombotic therapy for VTE Disease: second update of the CHEST Guideline and Expert Panel Report. Chest 160:e545\u2013e608. https:\/\/doi.org\/10.1016\/j.chest.2021.07.055","journal-title":"Chest"},{"key":"3002_CR21","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/j.amjcard.2018.08.053","volume":"122","author":"Y Yamashita","year":"2018","unstructured":"Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K et al (2018) Influence of baseline platelet count on outcomes in patients with venous thromboembolism (from the COMMAND VTE Registry). Am J Cardiol 122:2131\u20132141. https:\/\/doi.org\/10.1016\/j.amjcard.2018.08.053","journal-title":"Am J Cardiol"},{"key":"3002_CR22","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1161\/cir.0b013e318214914f","volume":"123","author":"MR Jaff","year":"2011","unstructured":"Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ et al (2011) Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 123:1788\u20131830. https:\/\/doi.org\/10.1161\/cir.0b013e318214914f","journal-title":"Circulation"},{"key":"3002_CR23","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1253\/circj.cj-88-0010","volume":"75","author":"MFI Ando","year":"2011","unstructured":"Ando MFI, Ito M, Kobayashi T, Masuda M, Miyahara Y, Nakanishi N et al (2011) Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009). Circ J: Official J Japanese Circulation Soc 75:1258\u20131281. https:\/\/doi.org\/10.1253\/circj.cj-88-0010","journal-title":"Circ J: Official J Japanese Circulation Soc"},{"key":"3002_CR24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/cvr\/cvab078","volume":"118","author":"P Joseph","year":"2022","unstructured":"Joseph P, Glynn R, Lonn E, Ramasundarahettige C, Eikelboom J, MacFadyen J et al (2022) Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. Cardiovasc Res 118:897\u2013903. https:\/\/doi.org\/10.1093\/cvr\/cvab078","journal-title":"Cardiovasc Res"},{"key":"3002_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1161\/circulationaha.107.709204","volume":"117","author":"W Ageno","year":"2008","unstructured":"Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW (2008) Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117:93\u2013102. https:\/\/doi.org\/10.1161\/circulationaha.107.709204","journal-title":"Circulation"},{"key":"3002_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.atherosclerosis.2018.02.035","volume":"271","author":"F Zaccardi","year":"2018","unstructured":"Zaccardi F, Kunutsor SK, Seidu S, Davies MJ, Khunti K (2018) Is the lower risk of venous thromboembolism with statins related to low-density-lipoprotein reduction? A network meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis 271:223\u2013231. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.02.035","journal-title":"Atherosclerosis"},{"key":"3002_CR27","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/jth.13587","volume":"15","author":"N Arshad","year":"2017","unstructured":"Arshad N, Bj\u00f8ri E, Hindberg K, Isaksen T, Hansen JB, Braekkan SK (2017) Recurrence and mortality after first venous thromboembolism in a large population-based cohort. J Thromb Haemost 15:295\u2013303. https:\/\/doi.org\/10.1111\/jth.13587","journal-title":"J Thromb Haemost"},{"key":"3002_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","volume":"41","author":"JA Heit","year":"2016","unstructured":"Heit JA, Spencer FA, White RH (2016) The epidemiology of venous thromboembolism. J Thromb Thrombolysis 41:3\u201314. https:\/\/doi.org\/10.1007\/s11239-015-1311-6","journal-title":"J Thromb Thrombolysis"},{"key":"3002_CR29","doi-asserted-by":"publisher","first-page":"14804","DOI":"10.1038\/s41598-019-51374-8","volume":"9","author":"RM Kronenberg","year":"2019","unstructured":"Kronenberg RM, Beglinger S, Stalder O, M\u00e9an M, Limacher A, Beer JH et al (2019) Statin therapy and recurrent venous thromboembolism in the elderly: a prospective cohort study. Sci Rep 9:14804. https:\/\/doi.org\/10.1038\/s41598-019-51374-8","journal-title":"Sci Rep"},{"key":"3002_CR30","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1093\/eurheartj\/ehx107","volume":"38","author":"SK Kunutsor","year":"2017","unstructured":"Kunutsor SK, Seidu S, Khunti K (2017) Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. Eur Heart J 38:1608\u20131612","journal-title":"Eur Heart J"},{"key":"3002_CR31","doi-asserted-by":"publisher","first-page":"106931","DOI":"10.1093\/eurheartj\/ehx107","volume":"142","author":"H Zhu","year":"2022","unstructured":"Zhu H, Zheng H, Xu T, Liu X, Liu X, Sun L et al (2022) Effects of statins in primary and secondary prevention for venous thromboembolism events: a meta analysis. Vascul Pharmacol 142:106931. https:\/\/doi.org\/10.1093\/eurheartj\/ehx107","journal-title":"Vascul Pharmacol"},{"key":"3002_CR32","doi-asserted-by":"publisher","first-page":"105413","DOI":"10.1016\/j.phrs.2020.105413","volume":"165","author":"R Li","year":"2021","unstructured":"Li R, Yuan M, Yu S, Fu W, Yu W, Ling S et al (2021) Effect of statins on the risk of recurrent venous thromboembolism: a systematic review and meta-analysis. Pharmacol Res 165:105413. https:\/\/doi.org\/10.1016\/j.phrs.2020.105413","journal-title":"Pharmacol Res"},{"key":"3002_CR33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jclinepi.2016.06.005","volume":"79","author":"LG Hemkens","year":"2016","unstructured":"Hemkens LG, Benchimol EI, Langan SM, Briel M, Kasenda B, Januel JM et al (2016) The reporting of studies using routinely collected health data was often insufficient. J Clin Epidemiol 79:104\u2013111. https:\/\/doi.org\/10.1016\/j.jclinepi.2016.06.005","journal-title":"J Clin Epidemiol"},{"key":"3002_CR34","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.amjcard.2018.02.024","volume":"121","author":"P Chaffey","year":"2018","unstructured":"Chaffey P, Thompson M, Pai AD, Tafreshi AR, Tafreshi J, Pai RG (2018) Usefulness of statins for Prevention of venous thromboembolism. Am J Cardiol 121:1436\u20131440. https:\/\/doi.org\/10.1016\/j.amjcard.2018.02.024","journal-title":"Am J Cardiol"},{"key":"3002_CR35","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/nejmoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr., Kastelein JJ et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195\u20132207. https:\/\/doi.org\/10.1056\/nejmoa0807646","journal-title":"N Engl J Med"},{"key":"3002_CR36","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/s0140-6736(14)61368-4","volume":"385","author":"J Fulcher","year":"2015","unstructured":"Fulcher J, O\u2019Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B et al (2015) Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (London England) 385:1397\u20131405. https:\/\/doi.org\/10.1016\/s0140-6736(14)61368-4","journal-title":"Lancet (London England)"},{"issue":"16","key":"3002_CR37","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1001\/jama.1997.03540400055031","volume":"277","author":"PM Ridker","year":"1997","unstructured":"Ridker PM, Miletich JP, Hennekens CH, Buring JE (1997) Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 277(16):1305\u20131307. https:\/\/jamanetwork.com\/journals\/jama\/article-abstract\/415610","journal-title":"JAMA"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-03002-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03002-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T08:08:34Z","timestamp":1723190914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-03002-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["3002"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-03002-0","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,18]]},"assertion":[{"value":"7 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current study was conducted in accordance with the principles of the Declaration of Helsinki. We further confirm that any aspect of the work covered in this manuscript that has involved either experimental animals or human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Written informed consent from each patient was waived, because we used clinical information obtained in routine clinical practice. This method is concordant with the guidelines for epidemiological studies issued by the Ministry of Health, Labor, and Welfare in Japan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Dr. Yamashita received lecture fees from Bayer Healthcare, Bristol-Myers Squibb, Pfizer, and Daiichi-Sankyo and grant support from Bayer Healthcare and Daiichi-Sankyo. Dr. Morimoto reports lecture fees from Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Kowa, Kyocera, Novartis, and Toray and manuscript fees from Bristol-Myers Squibb and Kowa; he was on the advisory board for Sanofi. Dr. Kaneda received lecture fees from Bristol-Myers Squibb, Pfizer, and Daiichi-Sankyo. Dr. Nishimoto received lecture fees from Bayer Healthcare, Bristol-Myers Squibb, Pfizer, and Daiichi-Sankyo. Dr. Ikeda N. received lecture fees from Bayer Healthcare, Bristol-Myers Squibb, and Daiichi-Sankyo. Dr. Ikeda S. received lecture fees from Bayer Healthcare, Bristol-Myers Squibb and Daiichi-Sankyo. Dr. Ogihara received research funding from Bayer Healthcare. Dr. Koitabashi received lecture fees from Bayer Healthcare and grant support from Pfizer. All other authors reported that they have no relationships relevant to the contents of this paper to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}